| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-18143
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-18122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-51 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-125
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-01 |
| filingDate |
2000-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d7dfa7d03848aa4c5dda9e451cf2b0a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8bd7fe86789cb54cef60aad882027de8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_31f6a78df53dabad06c2238048234e14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a03b4d58268552520ee56bb4c4b211d0 |
| publicationDate |
2003-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2003087417-A1 |
| titleOfInvention |
Newcastle disease virus infectious clones, vaccines and diagnostic assays |
| abstract |
The invention relates to the process for generating infectious Newcastle disease virus (NDV) entirely from cloned full-length cDNA and to the use of vaccines and diagnostic assays generated with and derived from said process. The process offers the possibility to modify the NDV genome by means of genetic modification and allows the introduction of mutations, deletions and/or insertions. The process can be used to modify the antigenic make-up of NDV, thus allowing the generation of live NDV marker vaccines which can be serologically distinguished from NDV field strains. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10308913-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2014341950-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9387242-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2012122185-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7270990-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011311578-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110257562-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005186223-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110938711-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100801180-B1 |
| priorityDate |
1998-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |